Abstract
Clinical background
The bone has a unique healing potential after damage, resulting in tissue of ultimately the same quality, structure and architecture as before. High 
Critical size defects
A critical size defect is defined as the smallest size intra-osseous wound in a particular bone and species of animal that will not heal spontaneously [2] , or as a defect that shows less than 10% bony regeneration during the lifetime of the animal [3] . Furthermore, a defect can be characterized as 'critical size' when its length deficiency exceeds two to three times its diameter [4] .
Bone physiology -molecular cues and cellular responses
All available treatments for segmental bone defects are based upon specific molecular and cellular mechanisms. Hence, their function is better understood with an insight of basic bone physiology. [6] .
The structural unit of bone is called bone multicellular unit and consists of bone-resorbing cells (osteoclasts), bone-forming cells (osteoblasts, osteocytes and bone-lining cells), their precursor cells and other associated cells, such as endothelial and nerve cells [5]. Osteoclasts form a bone-resorbing front and are followed by osteoblasts producing new bone. Those osteoblasts that are trapped within the newly formed bone finally differentiate into osteocytes, while those on the surface into lining cells. Osteogenesis is the initial production of bone and includes intramembranous and endochondral ossification. Bone modelling involves the formation of bone's shape and structure by the independent actions of bone remodelling units. Furthermore, bone is being constantly renewed by bone remodelling via the coupled actions of osteoclasts and osteoblasts
Osteoclasts [35] .
The skeletal stem cells, originally termed colony forming unitsfibroblasts are of stromal nature, meaning that they do not bear any haematopoietic or endothelial characteristics and are thus found to the non-haematopoietic tissue which is included in the intact bone marrow [36, 37] .
Furthermore, bone marrow stromal cells form clonal colonies under certain conditions [38] . Multipotency is another characteristic of skeletal stem cells. They have the potential to differentiate into bone, cartilage, tendon, muscle and fat both in vitro and in vivo [36, 39, 40] .
In [11, 47] .
Skeletal stem cells can be transduced using oncoretrovectors and lentivectors, which have been proved very efficient and neutral in respect to the cells' growth and differentiation properties [48] . The use of molecular engineering allows for the production of stromal cell strains that overexpress specific genes [36] .
After in vivo transplantation of skeletal stem cells, formation of bone and bone marrow occurs. MSCs are able to regenerate segmental bone defects by direct orthotopic placement in conjunction with appropriate scaffolds [41] . They have been used successfully in the treatment of segmental bone defects in various animal models [49, 50] [51] [52] [53] [54] . [55] [56] [57] . Later, Sampath and Reddi developed a BMP bioassay for ectopic bone formation, based on the activity of alkaline phosphatase and calcium content in the newly formed bone [58] . Reddi [59, 60] . In the late 1980s, BMPs were produced and isolated using recombinant DNA methodologies [61] . [62] .
Osteoinductive factors

The most extensively studied and most widely used osteoinductive factors for the treatment of bone defects are BMPs. Based on the observation of previous researchers that intramuscular injection of bone extracts can induce ectopic bone formation, Urist discovered that a mix of proteins was responsible for bone regeneration, which he named BMPs
and Huggins proposed that BMPs induce bone marrow progenitor cells to produce bone cells, leading to bone regeneration
BMPs are members of the TGF-␤ superfamily and include 18 known proteins, among which BMP-2, BMP-4, BMP-6, BMP-7 and BMP-9 have full osteoinductive potential. They are active as homodimers or heterodimers. Heterodimers have been found to be more effective in inducing bone formation, as shown by the higher yields of alkaline phosphatase in cell cultures
BMPs bind to two types of cell surface receptors, BMPRI and BMPRII [63] . These receptors are serine-threonine kinases and trigger specific intracellular pathways. Different combinations of type I and type II receptors provide different and specific signals which lead to distinct cell effects [64] . [66] .
BMP activity is subjected to regulation by specific proteins that act as antagonists and include noggin, chordin, follistatin, gremlin, betaglycan and crypto [12]. These proteins are extracellular and inhibit BMP binding to cell receptors. Upon BMP binding, BMP receptors phosphorylate certain intracellular signal transducing proteins, called receptor-regulated Smads (R-Smads), which include Smad1, Smad5, Smad8 and Smad9. R-Smads form a complex with a common-partner Smad (Co-Smad). Smad4 is so far the only described Co-Smad. Two RSmads and one Co-Smad form a heterotrimeric complex, which is translocated into the nucleus and modulates the function of transcription factors, among which Runx2 is the most important one [65], and ultimately gene expression. Inhibitory Smads (I-Smads) negatively regulate Smad signal transduction. Additionally, Smad ubiquitin regulatory factors (Smurfs) induce the degradation of Smads and control BMP signal transduction [12]. BMP signalling also involves MAPK pathways, including the ERK, the c-Jun N-terminal kinase and the p38 MAPK cascades
Osx is another transcription factor induced by BMP signalling and probably other pathways including MAPK pathway [67] . Osx and Runx2 are the most thoroughly studied transcription factors activated by BMP signalling. Finally, menin also regulates Runx2-induced gene expression during the commitment of MSCs into osteoblast differentiation [68] .
The TGF-␤-activin and BMP pathways share similar signalling molecules and thus compete with each other. Expression of TGF-␤ induces I-Smads, which regulate the BMP signalling effects [69] . The Notch, EGF, Wnt, IGF and FGF pathways also interact with the BMP-Smad pathway [12] .
Several preclinical studies in animal models have evaluated the effectiveness of BMPs in the treatment of segmental bone defects [70] [71] [72] . These studies encouraged researchers to evaluate the usefulness of BMPs in treating bone defects in human beings [73] [74] [75] [76] [77] [78] .
Recombinant [79] . [80, 81] . According to other studies, IGF-1 induces both bone resorption and formation [82] .
Another way of improving BMP effectiveness is chemical modification [12]. Finally, BMPs' bioactivity could be enhanced by the production of rhBMP heterodimers. IGFs have also been studied for their effectiveness in the treatment of segmental bone defects. Their anabolic role in bone formation has been outlined by many researchers
Prostaglandins (PGs) are another category of substances found in large quantities in bone tissue. Among them, PGE2 is the most potent one [83] . There are four prostaglandin receptor types, EP1, EP2, EP3 and EP4 [84] . Depending [85] . The application of PGE2 to a fracture site has been found to significantly stimulate osteoblastic activity [86] .
A novel approach for the promotion of osteoinductive growth factors effectiveness and the enhancement of bioartificial bone tissues is gene therapy [87] . Cell transfection has been achieved with viral vectors, which provide efficient and stable transfection [88] . Non-viral vectors, such as transfection reagents, and matrix-mediated gene transfer are approaches that avoid the use of potentially harmful viral vectors [89] . For the time being, issues like phenotypical stability, application techniques and long-term effects hamper extensive application of gene therapy [90] . [94] .
Biomaterials and scaffolds
The bioabsorbable polymer can be reinforced with a bioactive ceramic already described [95, 96] . The aim is to obtain a material that displays similar mechanical properties to bone, can integrate effectively with bone tissue and shows a degradation rate that matches the lesion's healing period. Finally, the coupling of polymers and proteins on the surface of the material can improve its bioactivity [91] .
Scaffolds are three-dimensional porous structures that need to fulfil certain criteria in order to be used in tissue engineering. These include biocompatibility, biodegradability, porosity and mechanical analogy to the load-bearing bone [97] .
A wide spectrum of both natural and synthetic materials is being investigated for the construction of scaffolds for bone tissue engineering, including the aforementioned ceramics and polymers. PLA and PGA are the most widely used polymers for bone tissue engineering, as they provide better control of their physicochemical properties and have been successfully employed in clinical applications [98] . Interestingly [90] .
Adding a vascularized periosteal flap to the scaffold led to a significant increase in bone formation. Co-implantation of perivascular cell precursors and endothelial cells in engineered constructs leads to long-lasting, stable microvessels in vivo, which are fully functional for more than 1 year [105] . Recent studies have shown that the combination of angiogenic and osteogenic factors can stimulate bone healing and regeneration [106, 107] . In a rat animal model, the application of BMP-3 on a muscle flap, covered with DBM and enclosed in pre-shaped moulds, led to the transformation of the muscle tissue into vascularized bone grafts, in the shape of femoral heads and mandibles [108] 
